Last reviewed · How we verify
Flublok Quadrivalent vaccine
Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates immune response against four strains of influenza virus.
Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates immune response against four strains of influenza virus. Used for Prevention of influenza A and B in adults and children.
At a glance
| Generic name | Flublok Quadrivalent vaccine |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Drug class | Recombinant protein vaccine |
| Target | Influenza hemagglutinin (HA) antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Unlike traditional egg-based flu vaccines, Flublok uses recombinant hemagglutinin (HA) antigens produced in insect cells to generate protective antibodies against two influenza A strains (H1N1 and H3N2) and two influenza B strains. This cell-culture-based approach allows faster production and avoids egg allergen concerns while providing quadrivalent protection.
Approved indications
- Prevention of influenza A and B in adults and children
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. (PHASE3)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above (PHASE1, PHASE2)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flublok Quadrivalent vaccine CI brief — competitive landscape report
- Flublok Quadrivalent vaccine updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI